1. Home
  2. SCYX vs GROV Comparison

SCYX vs GROV Comparison

Compare SCYX & GROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$4.44

Market Cap

51.4M

Sector

Health Care

ML Signal

N/A

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

N/A

Current Price

$1.01

Market Cap

52.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
SCYX
GROV
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
51.4M
52.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SCYX
GROV
Price
$4.44
$1.01
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$3.00
$1.60
AVG Volume (30 Days)
64.8K
86.9K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
55.26
EPS
N/A
N/A
Revenue
$257,000.00
$173,716,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$608.78
$6.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.86
52 Week High
$6.09
$1.57

Technical Indicators

Market Signals
Indicator
SCYX
GROV
Relative Strength Index (RSI) 38.72 49.48
Support Level $0.67 $0.86
Resistance Level $5.56 $1.15
Average True Range (ATR) 0.34 0.08
MACD -0.12 0.01
Stochastic Oscillator 0.63 61.95

Price Performance

Historical Comparison
SCYX
GROV

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.

Share on Social Networks: